KEYNOTE‐811: Potential to revise first‐line therapy for metastatic human epidermal growth factor receptor 2‐positive gastric cancer

Ítems similars

• 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
  per: Takuo Yamai, et al.
  Publicat: (2022-04-01)
• Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
  per: Lyu Ning, et al.
  Publicat: (2022-01-01)
• KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
  per: Yanhong Deng, et al.
  Publicat: (2015-08-01)
• Tracheoesophageal fistula and esophageal perforation in a patient with advanced gastroesophageal junction tumor post ramucirumab treatment. A case report and literature review
  per: Ahmed Abdalhadi, et al.
  Publicat: (2023-03-01)
• Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma
  per: Ying-Ao Liu, et al.
  Publicat: (2026-06-01)